Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

DBVT

DBV Technologies ADR

Apr 02 • 10:31AM ET

6.58

Dollar change +0.12
Percentage change 1.86	%

Healthcare • Biotechnology • France • NASD

Peers: ALNY VRNA RARE EHAB ADMA XOMA ARRY AXSM ANAB ASND

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.85	Insider Own	0.07%	Shs Outstand	20.51M	Perf Week	62.47%
Market Cap	134.96M	Forward P/E	-	EPS next Y	-7.58	Insider Trans	-21.18%	Shs Float	20.50M	Perf Month	53.02%
Income	-113.90M	PEG	-	EPS next Q	-0.24	Inst Own	13.01%	Short Float	1.66%	Perf Quarter	109.00%
Sales	0.00M	P/S	-	EPS this Y	-254.45%	Inst Trans	-80.29%	Short Ratio	0.79	Perf Half Y	88.00%
Book/sh	2.81	P/B	2.34	EPS next Y	-82.78%	ROA	-91.60%	Short Interest	0.34M	Perf Year	-15.64%
Cash/sh	1.58	P/C	4.15	EPS next 5Y	-	ROE	-135.93%	52W Range	2.20 - 8.32	Perf YTD	112.94%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.11%	ROI	-186.50%	52W High	-20.89%	Beta	-0.61
Dividend TTM	-	Quick Ratio	2.22	Sales past 5Y	0.00%	Gross Margin	-	52W Low	198.48%	ATR (14)	0.66
Dividend Ex-Date	-	Current Ratio	2.22	EPS Y/Y TTM	-52.69%	Oper. Margin	-	RSI (14)	66.50	Volatility	15.45% 11.24%
Employees	-	Debt/Eq	0.55	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	18.17
Option/Short	No / No	LT Debt/Eq	0.26	EPS Q/Q	-93.48%	Payout	-	Rel Volume	1.12	Prev Close	6.46
Sales Surprise	-45.45%	EPS Surprise	-9.09%	Sales Q/Q	-	Earnings	Mar 24 BMO	Avg Volume	431.80K	Price	6.58
SMA20	32.97%	SMA50	44.18%	SMA200	61.45%	Trades		Volume	96,063	Change	1.86%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-04-23	Upgrade	Societe Generale	Hold → Buy
Dec-16-22	Downgrade	Goldman	Neutral → Sell
May-10-22	Downgrade	Goldman	Buy → Neutral	$6 → $1.50
Sep-14-21	Upgrade	Societe Generale	Hold → Buy
Jan-22-21	Downgrade	Societe Generale	Hold → Sell
Nov-02-20	Upgrade	Societe Generale	Sell → Hold
Aug-06-20	Downgrade	Societe Generale	Buy → Sell
Aug-05-20	Reiterated	H.C. Wainwright	Buy	$25 → $14
Mar-17-20	Downgrade	Stifel	Buy → Hold	$18 → $6
Jan-09-20	Upgrade	Stifel	Hold → Buy	$10 → $18
Dec-16-19	Initiated	Citigroup	Buy
Sep-05-19	Resumed	Morgan Stanley	Equal-Weight
Jun-17-19	Initiated	Goldman	Buy
Dec-20-18	Downgrade	Stifel	Buy → Hold
Dec-20-18	Downgrade	Jefferies	Buy → Hold
Dec-20-18	Downgrade	BofA/Merrill	Buy → Underperform
Dec-20-18	Downgrade	Barclays	Overweight → Equal Weight
Oct-31-17	Upgrade	Societe Generale	Sell → Hold
Oct-24-17	Downgrade	Societe Generale	Buy → Sell
Oct-23-17	Downgrade	Morgan Stanley	Overweight → Equal-Weight

Show Previous Ratings

Mar-27-25 10:30PM	DBV Technologies Announces Financing of up to $306.9 Million ( 284.5 Million) to Advance Viaskin Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved (GlobeNewswire) +58.57%
Mar-24-25 03:09AM	DBV Now Plans BLA Submission For Viaskin Peanut Patch In Children 4 - 7-years-old In H1, 2026 (RTT News) -10.62%
02:30AM	DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin Peanut Patch in 4 7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results... (GlobeNewswire)
Feb-25-25 04:01PM	DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress (GlobeNewswire)
Jan-13-25 04:05PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire) +8.85% -14.23%
04:05PM	Loading…
Jan-08-25 04:05PM	DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study (GlobeNewswire) +10.37% +29.77%
Dec-12-24 09:59AM	DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids (Benzinga) +16.72%
Dec-11-24 04:05PM	DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin Peanut Patch in Toddlers 1 3 Years-Old (GlobeNewswire)
Dec-02-24 04:30PM	Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024 (GlobeNewswire) +7.05%
Nov-11-24 04:30PM	DBV Technologies Announces Plan to Implement ADS Ratio Change (GlobeNewswire) -6.07%
Nov-06-24 04:30PM	DBV Technologies Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-24-24 08:31AM	DBV Technologies price target raised to $7 from $5 at H.C. Wainwright (TipRanks) +23.14%
Oct-22-24 04:45PM	DBV Announces Positive Regulatory Updates for the Viaskin Peanut Patch in the United States and Europe (GlobeNewswire)
Oct-18-24 04:30PM	DBV Technologies to Participate in Upcoming ACAAI 2024 Congress (GlobeNewswire)
Oct-14-24 04:30PM	Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024 (GlobeNewswire)
04:30PM	Loading…
Sep-23-24 04:30PM	DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial (GlobeNewswire) -6.03%
Sep-04-24 04:30PM	DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.63%
Aug-02-24 04:30PM	Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (GlobeNewswire)
Jul-30-24 08:55PM	DBVT Stock Earnings: DBV Technologies Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:30PM	DBV Technologies Announces Filing of 2024 Half-Year Report ? Conditions for Accessing or Consulting the Report (GlobeNewswire)
04:30PM	DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results (GlobeNewswire)
Jul-29-24 01:30AM	DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 (GlobeNewswire)
Jul-08-24 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
Jun-05-24 04:30PM	DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-04-24 04:30PM	Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024 (GlobeNewswire)
May-31-24 09:51AM	DBV Technologies Announces Plan to Implement ADS Ratio Change (GlobeNewswire)
May-30-24 04:30PM	DBV Technologies to Participate in Upcoming EAACI 2024 Congress (GlobeNewswire)
May-17-24 04:30PM	DBV Technologies Announces Plan to Implement ADS Ratio Change (GlobeNewswire) +7.97%
May-16-24 04:30PM	DBV Technologies Announces Results of its 2024 Combined General Meeting (GlobeNewswire)
May-09-24 04:30PM	DBV Technologies to Participate in Upcoming Investor Conferences (GlobeNewswire) -17.77%
11:53PM	Loading…
May-07-24 11:53PM	DBVT Stock Earnings: DBV Technologies Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:30PM	DBV Technologies Reports First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Apr-25-24 04:30PM	Combined General Meeting of May 16, 2024 (GlobeNewswire)
Apr-04-24 04:43PM	Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024 (GlobeNewswire) -6.67% +10.00%
Mar-08-24 11:01AM	DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:33AM	DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document (GlobeNewswire)
Mar-07-24 10:52PM	DBVT Stock Earnings: DBV Technologies Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:30PM	DBV Technologies Reports Full Year 2023 Financial Results and Business Update (GlobeNewswire)
Mar-04-24 04:30PM	DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 (GlobeNewswire)
Feb-20-24 04:30PM	DBV Technologies to Participate in Upcoming AAAAI 2024 Congress (GlobeNewswire) -7.58%
Jan-16-24 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
Dec-04-23 04:30PM	Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (GlobeNewswire) -5.79% +6.21%
Nov-09-23 04:30PM	DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin Peanut in Toddlers (GlobeNewswire) -5.66%
Nov-06-23 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023 (GlobeNewswire)
Nov-02-23 04:30PM	DBV Technologies to Present New Data at ACAAI 2023 (GlobeNewswire)
Oct-31-23 04:30PM	DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-27-23 04:30PM	DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Oct-16-23 02:00AM	DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer (GlobeNewswire)
Oct-05-23 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023 (GlobeNewswire)
Sep-05-23 04:30PM	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire) +11.46% -5.71%
Jul-31-23 04:25PM	DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results (GlobeNewswire) -6.33% +8.78%
Jul-25-23 04:30PM	DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update (GlobeNewswire)
Jul-19-23 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023 (GlobeNewswire)
Jul-10-23 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
Jun-16-23 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023 (GlobeNewswire)
Jun-08-23 04:30PM	DBV Technologies to Participate in Upcoming EAACI Congress 2023 (GlobeNewswire)
Jun-06-23 05:00PM	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire)
May-10-23 05:30PM	DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin Peanut in Toddlers (GlobeNewswire) +12.12%
May-09-23 04:30PM	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire)
May-04-23 04:30PM	DBV Technologies Reports First Quarter 2023 Financial Results (GlobeNewswire) +5.77%
Apr-19-23 05:09PM	DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 3 Years After Receiving Pre-BLA Responses from FDA (GlobeNewswire)
Apr-12-23 04:30PM	DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting (GlobeNewswire)
Mar-24-23 04:30PM	Ordinary and Extraordinary General Meeting of April 12, 2023 (GlobeNewswire)
Mar-13-23 01:30AM	DBV Technologies Update (GlobeNewswire)
Mar-07-23 04:30PM	DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 7 Years Old (GlobeNewswire) +14.57%
Mar-02-23 05:30PM	DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document (GlobeNewswire) -5.52% +5.11%
04:30PM	DBV Technologies Reports Full Year 2022 Financial Results and Business Update (GlobeNewswire)
Feb-27-23 01:30AM	DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023 (GlobeNewswire)
Feb-21-23 04:30PM	DBV Technologies to Participate in Upcoming AAAAI 2023 Congress (GlobeNewswire)
Feb-10-23 04:30PM	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire)
Jan-23-23 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
Jan-04-23 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022 (GlobeNewswire)
Dec-23-22 01:30AM	DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial (GlobeNewswire) +22.03%
Dec-08-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2022 (GlobeNewswire)
Nov-22-22 04:30PM	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire) +5.34%
Nov-09-22 01:30AM	DBV Technologies to Highlight New Clinical Data at ACAAI 2022 (GlobeNewswire)
Nov-03-22 04:30PM	DBV Technologies Reports Third Quarter Financial Results and Business Update (GlobeNewswire)
Oct-31-22 04:30PM	DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update (GlobeNewswire)
Oct-20-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022 (GlobeNewswire)
Oct-03-22 04:30PM	DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors (GlobeNewswire)
Sep-21-22 05:45PM	DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial (GlobeNewswire) -7.24%
Sep-07-22 04:30PM	DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years (GlobeNewswire)
Sep-02-22 04:30PM	DBV Technologies to Present at Upcoming Investor Conferences (GlobeNewswire) +12.95% +7.80%
Aug-10-22 04:50PM	Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space (GlobeNewswire)
Aug-01-22 04:30PM	DBV Technologies Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-27-22 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire) +5.83%
Jul-20-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022 (GlobeNewswire) +6.99%
Jun-28-22 06:15PM	DBV Technologies to Participate in Upcoming EAACI 2022 Congress (GlobeNewswire)
Jun-16-22 01:30AM	DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York (GlobeNewswire)
Jun-09-22 02:55AM	DBV Technologies Announces Private Placement Financing of $194 Million (GlobeNewswire) +79.56%
Jun-07-22 04:30PM	DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers (GlobeNewswire) +18.30%
May-17-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022 (GlobeNewswire) +5.74%
May-12-22 04:30PM	DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting (GlobeNewswire)
May-04-22 07:30PM	DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM) (GlobeNewswire) +5.51%
May-02-22 05:00PM	DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq (GlobeNewswire) +7.36% -8.30%
04:00PM	DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results (GlobeNewswire)
Apr-25-22 07:30PM	Correction: DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments (GlobeNewswire)
04:30PM	DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments (GlobeNewswire)
Apr-21-22 04:30PM	Ordinary and Extraordinary General Meeting of May 12, 2022 (GlobeNewswire)
Apr-14-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2022 (GlobeNewswire)

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stephane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mohideen Pharis	Chief Medical Officer	Jan 30 '25	Sale	0.85	600	510	110,510	Jan 31 04:59 PM
Mohideen Pharis	Chief Medical Officer	Nov 25 '24	Sale	0.57	565	322	111,110	Nov 27 04:15 PM
Mohideen Pharis	Chief Medical Officer	Nov 22 '24	Sale	0.53	342	181	111,675	Nov 27 04:15 PM
Mohideen Pharis	Chief Medical Officer	Nov 21 '24	Sale	0.54	2,350	1,269	112,017	Nov 25 05:13 PM
Mohideen Pharis	Chief Medical Officer	Jul 29 '24	Sale	0.98	1,785	1,749	79,367	Jul 31 05:32 PM
Mohideen Pharis	Chief Medical Officer	May 24 '24	Sale	1.36	660	898	81,152	May 29 04:15 PM
Mohideen Pharis	Chief Medical Officer	May 22 '24	Sale	1.38	382	527	81,812	May 29 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DBVT

DBV Technologies ADR

Upgrade your FINVIZ experience